Speakers
Claire Harris
VP Head of Biology
Gyroscope Therapeutics
Track B - Day 1 AM
12:30 pm | Supplementing Complement Factor I as a Therapeutic Strategy in Age-Related Macular Degeneration
Rosario Fernandez-Godino
Assistant Professor of Ophthalmology
Harvard Medical School; Drug Discovery & Disease Biology at Intergalactic Therapeutics
Christopher J. Campbell
Chief Scientific Officer
Aurin Biotech Inc.
Track A - Day 1 PM
3:00 pm | More Complement Crosstalk: The Ins and Outs of Sublytic MAC
Tim Higenbottam
Professor
Akari Therapeutics
Day Two
Thursday 13th December 2018
3:30 pm | Clinical Impacts of Controlling Dysregulation of the Terminal Complement Pathway and LTB4
Anita Hill
Vice President, Global Medical Affairs Lead Haematology & Nephrology, Consultant Clinical Development
Alexion
Day One
Thursday 13th December 2018
9:30 am | SWOT Analysis Panel Discussion Topics to be Addressed
Moshe Vardi
VP, R&D Global Medicine Team Leader Hematology/Nephrology
Alexion
Track B - Day 1 PM 2
4:00 pm | Validating Robust Combination Strategies Within the Context of the Patient Continuum of Care
Shamsah Kazani
Sr. Medical Director Hematology/Nephrology
Alexion
Day Two
Thursday 13th December 2018
2:30 pm | Complement Inhibition in the Setting of COVID-19
Sanjay Keswani
EVP & Chief Medical Officer
Annexon Biosciences
Day One
Thursday 13th December 2018
10:00 am | A Precision Medicine Approach to Classical Complement Mediated Diseases: Identifying the Right Patients to Achieve Better Outcomes
Lukas Scheibler
Chief Innovation Officer
Apellis
Track B - Day 1 AM
12:00 pm | To Be Announced
Inge Van de Walle
Principal Scientist
argenx
Day Two
Thursday 13th December 2018
12:30 pm | Upstream Complement Inhibition in Peripheral Auto- Immune Neuromuscular Neuropathies
Yingying Zhang
Postdoctoral Fellow
Boston Children’s Hospital (Michael Carroll’s lab)
Track A - Day 1 AM
12:30 pm | Spatial Transcriptomic Profiling of the Complement System in the Brain
Paul Morgan
Professor of Immunology
Cardiff University
Track A - Day 1 AM
11:30 am | Complement in Neurological Diseases: Roles in Pathology and Target for Therapy
Daniel Benjamin
Chief Executive Officer
Cascade Biotechnology Inc.
Day Two
Thursday 13th December 2018
12:00 pm | Cascade Biotechnology: Novel Therapeutic Opportunities Using Complement Depletion
Grant Blouse
Senior Vice President, Translational Research
Catalyst Biosciences
Day Two
Thursday 13th December 2018
11:30 am | Engineering Complement Factor I as a Protease Medicine: Replacement Therapy and Tuning Potency and Specificity for Complement-Mediated Disorders
Frank Baas
Chief Scientific Officer
Complement Pharma
Track B - Day 1 PM
3:00 pm | Terminal Pathway Inhibitors for Neurodegenerative Disorders
Sandra Wymann
Senior Manager, Translational Research
CSL Behring AG
Day Two
Thursday 13th December 2018
10:00 am | Recombinant Truncated Human CR1 as a Novel Complement Inhibitor
Renfeng Guo
Chief Scientific Officer
InflaRx N.V.
Jesse Hanson
Senior Scientist
Genentech, Inc
Track B - Day 1 PM
2:30 pm | Classical Pathway Activation in Neurodegenerative Disease
Edward F. Patz
Chief Executive Officer
Grid Therapeutics
Track A - Day 1 PM
2:30 pm | Complement Factor H as a Novel Drug Target for Cancer
Ruchi Sharma
Staff Scientist
National Eye Institute/NIH
Stephen Poor
Director External Opportunities & Translational Biomarkers
Novartis Institutes for Biomedical Research, Department of Ophthalmology
Track B - Day 1 AM
11:30 am | Roles of Systemic vs Local Complement Activation in Macular Degeneration
Shelia M. Violette
Co-Founder, Chief Scientific Officer & President of Research
Q32 Bio
Day Two
Thursday 13th December 2018
9:30 am | The Potential for Tissue Targeted Complement Inhibition: Generation of a Novel Therapeutic Platform
Michael Storek
Head of Complement Cluster
Sanofi
Day One
Thursday 13th December 2018
9:30 am | SWOT Analysis Panel Discussion Topics to be Addressed
9:20 am | Chair’s Opening Remarks
Curtis Rambaran
VP Head Clinical Science
Silence Therapeutics
Day Two
Thursday 13th December 2018
2:00 pm | siRNA Targeting Complement Protein 3 (C3) for Treatment of Patients with C3 Glomerulopathy (C3G)
Jeffry Lawrence
Interim Vice President, Clinical Development
Solid Biosciences
Day One
Thursday 13th December 2018
9:30 am | SWOT Analysis Panel Discussion Topics to be Addressed
Day Two
Thursday 13th December 2018
5:00 pm | Chair’s Closing Remarks
8:50 am | Chair’s Opening Remarks
Petra Duda
Head of Development – Zilucoplan
UCB
Track B - Day 1 PM
2:00 pm | Complement C5 Inhibition in Immune- Mediated Necrotizing Myopathy (IMNM)
Dorothy Schafer
Associate Professor of Neurobiology
UMass Medical School
Track A - Day 1 AM
12:00 pm | Complement-Mediated Synapse Loss: A Viable Therapeutic Target in Multiple Sclerosis
Hung D. Nguyen
Assistant Professor of Medicine
University of Central Florida College of Medicine
Track A - Day 1 PM
2:00 pm | Complement Targeting Therapies: A Promising Approach for the control of Graft-versus-host Disease and Tumor Relapse
Michael Holers
Professor of Medicine & Immunology
University of Colorado School of Medicine
Day Two
Thursday 13th December 2018
9:00 am | Next-Gen Complement Therapeutics: Opportunities for Indication Expansion and Tissue Targeted Immunomodulation
Dmitri Simberg
Associate Professor
University of Colorado